Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma

Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma Letters 4. Hemminki K, Vaittinen P, Dong C, Easton D. Sibling risks in cancer: clues to tial therapy to control new metastasis outside the liver is an- recessive or X-linked genes? Br J Cancer. 2001;84(3):388-391. doi:10.1054/bjoc. other concern that requires future consideration. 2000.1585 5. Bevier M, Sundquist K, Hemminki K. Risk of breast cancer in families of Xu Yang, MD multiple affected women and men. Breast Cancer Res Treat. 2012;132(2):723-728. Jie Pan, MD doi:10.1007/s10549-011-1915-2 Haitao Zhao, MD 6. Mukama T, Fallah M, Tian Y, et al. Risk-tailored starting age of breast cancer screening based on women’s reproductive profile: a nationwide cohort study. Eur J Cancer. 2020;124:207-213. doi:10.1016/j.ejca.2019.10.011 Author Affiliations: Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Yang, Zhao); Department of Radiology, Peking Union Locoregional Therapy Plus Systemic Chemotherapy Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Pan). in Unresectable Intrahepatic Cholangiocarcinoma To the Editor The study by Cercek et al in JAMA Oncology was Corresponding Author: Haitao Zhao, MD, Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and inspiring. It detailed a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma

JAMA Oncology , Volume 6 (6) – Jun 9, 2020

Loading next page...
 
/lp/american-medical-association/locoregional-therapy-plus-systemic-chemotherapy-in-unresectable-61UYg51h2Q
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.0340
Publisher site
See Article on Publisher Site

Abstract

Letters 4. Hemminki K, Vaittinen P, Dong C, Easton D. Sibling risks in cancer: clues to tial therapy to control new metastasis outside the liver is an- recessive or X-linked genes? Br J Cancer. 2001;84(3):388-391. doi:10.1054/bjoc. other concern that requires future consideration. 2000.1585 5. Bevier M, Sundquist K, Hemminki K. Risk of breast cancer in families of Xu Yang, MD multiple affected women and men. Breast Cancer Res Treat. 2012;132(2):723-728. Jie Pan, MD doi:10.1007/s10549-011-1915-2 Haitao Zhao, MD 6. Mukama T, Fallah M, Tian Y, et al. Risk-tailored starting age of breast cancer screening based on women’s reproductive profile: a nationwide cohort study. Eur J Cancer. 2020;124:207-213. doi:10.1016/j.ejca.2019.10.011 Author Affiliations: Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Yang, Zhao); Department of Radiology, Peking Union Locoregional Therapy Plus Systemic Chemotherapy Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Pan). in Unresectable Intrahepatic Cholangiocarcinoma To the Editor The study by Cercek et al in JAMA Oncology was Corresponding Author: Haitao Zhao, MD, Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and inspiring. It detailed a

Journal

JAMA OncologyAmerican Medical Association

Published: Jun 9, 2020

References